A Framework for the Use of Wearable Medical Devices in Regulatory Clinical Trials

Published Jun 19, 2018

Value in Health Reports on Recommendations From the ePRO Consortium

 Lawrenceville, NJ, USA—June 19, 2018—Value in Health, the official journal of ISPOR (the professional society for health economics and outcomes research), announced today the publication of new guidance regarding the selection and evaluation of wearable devices for use in regulatory trials and to support labeling claims. The report, Selection of and Evidentiary Considerations for Wearable Devices and Their Measurements for Use in Regulatory Decision Making: Recommendations from the ePRO Consortium, was published in the June 2018 issue of Value in Health. The consortium members determined that the identification of a device appropriate for use in a clinical trial or drug development program requires the consideration of three factors: 1) Is the wearable device or sensor safe to use? 2) Are the device and vendor suitable for the trial objectives and patient population studied? and 3) Is there satisfactory evidence of data validity and reliability to confirm that the device provides the required level of measurement accuracy and precision in measuring the concept of interest? These three factors, and the recommendations that flow from them as detailed in the report, are based on the current literature, the regulatory guidance available to date, and the expert consensus of member representatives of the Electronic Patient-Reported Outcome (ePRO) Consortium, a technology industry research group. “Although there remains a lack of specific guidance from regulatory bodies on the use of wearables in clinical trial programs, we believe this work provides a robust framework for the adoption of wearables in regulatory trials,” said lead author Bill Byrom, PhD, ICON Clinical Research, Marlow, Buckinghamshire, United Kingdom. “Although including wearable devices in clinical trial protocols may require some additional evidence gathering or generation, we believe the reward for this effort will be substantial.”

###

ABOUT ISPOR ISPOR, the professional society for health economics and outcomes research (HEOR), is an international, multistakeholder, nonprofit dedicated to advancing HEOR excellence to improve decision making for health globally. The Society is the leading source for scientific conferences, peer-reviewed and MEDLINE®-indexed publications, good practices guidance, education, collaboration, and tools/resources in the field. Web: www.ispor.org | LinkedIn: http://bit.ly/ISPOR-LIn | Twitter: www.twitter.com/ISPORorg (@ISPORorg) | YouTube: www.youtube.com/user/ISPORorg/videos | Facebook: www.facebook.com/ISPORorg | Instagram: www.instagram.com/ISPORorg ABOUT VALUE IN HEALTH Value in Health (ISSN 1098-3015) is an international, indexed journal that publishes original research and health policy articles that advance the field of health economics and outcomes research to help healthcare leaders make evidence-based decisions. The journal’s 2016 impact factor score is 4.235. Value in Health is ranked 3rd out of 77 journals in health policy and services, 7th out of 347 journals in economics, and 9th out of 90 journals in healthcare sciences and services. Value in Health is a monthly publication that circulates to more than 10,000 readers around the world. Web: www.ispor.org/valueinhealth_index.asp | Twitter: www.twitter.com/ISPORJournals

Related Stories

The Ozempic Paradox: How Spending Billions on Weight-Loss Drug Would Actually Reduce Overall Medicare Costs

Oct 14, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a landmark study by researchers at the University of Washington, Curta, Inc, and the University of North Carolina showing that broad Medicare coverage of semaglutide in diabetes, obesity, and liver disease could generate significant cost savings while delivering substantial health benefits to beneficiaries. The report, “Comprehensive Access to Semaglutide: Clinical and Economic Implications for Medicare,” was published in the October 2025 issue of Value in Health.

ISPOR Launches New Content on Whole Health

Sep 23, 2025

ISPOR announced that it has launched new website content on whole health, a topic of increasing importance as health systems across the globe grapple with providing the best possible healthcare to patients within constrained budgets.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×